NATO Innovation Fund invests in Basecamp Research
Funding Provisional 90% confidence first seen
Basecamp Research raised a $140 million Series C that included investment from the NATO Innovation Fund, alongside backers such as Nvidia and Anthropic. The round valued the company at $800 million and was described as oversubscribed, with funds earmarked for training new EDEN AI foundation-model versions and advancing preclinical, in-body cell therapies that aim to edit DNA directly in patients. The deal matters as it signals continued NATO Innovation Fund participation in advanced AI-enabled biotech efforts moving toward clinical translation, though Basecamp remains preclinical with no clinical-trial date disclosed.
The deal
Basecamp Research $140 million Series C · announced 23 Sep 2026
Investors S32 Anthropic NVIDIA NATO Anthology Fund NATO Innovation Fund
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Basecamp Research raised a $140 million Series C at an $800 million valuation, with participation from the NATO Innovation Fund alongside Nvidia and Anthropic. The company said the funding will be used to train new versions of its EDEN foundation model and advance preclinical in-body cell therapies designed to edit DNA directly in patients.
- Why it matters
- For leaders evaluating AI-biotech partnerships or competitive positioning, this shows NATO Innovation Fund capital continuing to flow into AI-enabled life sciences programs that are moving closer to clinical application. The combination of strategic investors and earmarked funding for both model development and therapeutic programs suggests sustained investor appetite for platform-plus-application companies, even though commercial and clinical milestones have not yet been disclosed.
- Evidence
- The event is supported by a single Tech Funding News AI report stating that Basecamp Research raised the round, naming Nvidia, Anthropic, and the NATO Innovation Fund as backers and describing the intended use of proceeds. Because the coverage comes from one outlet and does not cite independent confirmation beyond the financing details presented, support is directionally clear but limited in independence.
- What remains uncertain
- Basecamp remains preclinical, and the coverage gives no clinical-trial start date, development timeline, or regulatory pathway, so the timing and feasibility of translation into patients are still unclear. It is also not disclosed how large the NATO Innovation Fund's participation was or whether its involvement implies broader defense, biosecurity, or commercialization priorities.
- Monitor next
- Watch for a concrete clinical-development signal such as an IND-enabling milestone, named trial timeline, or regulatory filing tied to Basecamp's in-body cell therapy programs.
Analytical support, not advice — assumptions and open questions stated above.